Inside Nephrology: A Weekly Review
Nefrologia
Advances in Kidney Disease Management and Therapeutics
This week's nephrology update covers groundbreaking microbiome engineering for hyperoxaluria, emerging ADPKD therapies, improved diagnostic guidelines for AL amyloidosis and UTIs, culinary medicine approaches for CKD, and advances in renal cancer and transplant care.
Bibliography
1. Controlled colonization of the human gut with a genetically engineered microbial therapeutic.
Authors: Whitaker WR, Russ ZN, Stanley Shepherd E, et al.
Journal: Science (New York, N.Y.), 2025 Jul 17
PMID: 40674481
DOI: 10.1126/science.adu8000
2. Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.
Authors: Chen CY, Hadla M, Khambati I, et al.
Journal: Kidney360, 2026 Jul 1
PMID: 41385299
DOI: 10.34067/KID.0000001109
3. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.
Authors: Kukreti V, Seftel M, Aguirre MA, et al.
Journal: Blood advances, 2026 Jul 28
PMID: 41592868
DOI: 10.1182/bloodadvances.2025017073
4. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.
Authors: Loupy A, Aubert O, Orandi BJ, et al.
Journal: BMJ (Clinical research ed.), 2019 Sep 17
PMID: 31530561
DOI: 10.1136/bmj.l4923
5. The EFLM European Urinalysis Guideline 2023.
Authors: Kouri TT, Hofmann W, Falbo R, et al.
Journal: Clinical chemistry and laboratory medicine, 2024 Aug 27
PMID: 38534005
DOI: 10.1515/cclm-2024-0070
6. Culinary Medicine for CKD.
Authors: Schlueter R, Cooke J, Isaacson KL, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Jul 1
PMID: 40526439
DOI: 10.2215/CJN.0000000785
7. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.
Authors: Heerspink HJL, Soler M, Beernink JM, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Jul 1
PMID: 42308057
DOI: 10.2215/CJN.0000001051
8. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Authors: Motzer RJ, Escudier B, McDermott DF, et al.
Journal: The New England journal of medicine, 2015 Nov 5
PMID: 26406148
DOI: 10.1056/NEJMoa1510665
9. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Authors: Torres VE, Chapman AB, Devuyst O, et al.
Journal: The New England journal of medicine, 2012 Dec 20
PMID: 23121377
DOI: 10.1056/NEJMoa1205511
Authors: Whitaker WR, Russ ZN, Stanley Shepherd E, et al.
Journal: Science (New York, N.Y.), 2025 Jul 17
PMID: 40674481
DOI: 10.1126/science.adu8000
2. Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.
Authors: Chen CY, Hadla M, Khambati I, et al.
Journal: Kidney360, 2026 Jul 1
PMID: 41385299
DOI: 10.34067/KID.0000001109
3. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.
Authors: Kukreti V, Seftel M, Aguirre MA, et al.
Journal: Blood advances, 2026 Jul 28
PMID: 41592868
DOI: 10.1182/bloodadvances.2025017073
4. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.
Authors: Loupy A, Aubert O, Orandi BJ, et al.
Journal: BMJ (Clinical research ed.), 2019 Sep 17
PMID: 31530561
DOI: 10.1136/bmj.l4923
5. The EFLM European Urinalysis Guideline 2023.
Authors: Kouri TT, Hofmann W, Falbo R, et al.
Journal: Clinical chemistry and laboratory medicine, 2024 Aug 27
PMID: 38534005
DOI: 10.1515/cclm-2024-0070
6. Culinary Medicine for CKD.
Authors: Schlueter R, Cooke J, Isaacson KL, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Jul 1
PMID: 40526439
DOI: 10.2215/CJN.0000000785
7. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.
Authors: Heerspink HJL, Soler M, Beernink JM, et al.
Journal: Clinical journal of the American Society of Nephrology : CJASN, 2026 Jul 1
PMID: 42308057
DOI: 10.2215/CJN.0000001051
8. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Authors: Motzer RJ, Escudier B, McDermott DF, et al.
Journal: The New England journal of medicine, 2015 Nov 5
PMID: 26406148
DOI: 10.1056/NEJMoa1510665
9. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Authors: Torres VE, Chapman AB, Devuyst O, et al.
Journal: The New England journal of medicine, 2012 Dec 20
PMID: 23121377
DOI: 10.1056/NEJMoa1205511
